U-Chart Analysis:ROHTO PHARMACEUTICAL CO.,LTD.:4527

※The values of financial statements might be different from the actual ones. Please confirm the original. [instructions]

Main FunctionHelp Company NameHelp CodeHelp Types of IndustryHelp Market Name Fiscal Year End Year of Listing
Browse U-Chart Add to 'Companies Comparison' list Compare Lustrum Ullet index ROHTO PHARMACEUTICAL CO.,LTD. Go to web site 4527 Medicals 1st TSE March 1, 2000 1961.
Analysis u.gifU-Chart AnalysisHelp hikaku.gifAdd to 'Companies Comparison' listHelp u2.gifCompare LustrumHelp mark.gifUllet indexHelp
Accounts Information Balance Sheet Profit and Loss Account Cash Flow Statement
Display

ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet(B/S)

[Show - Hide] U-Chart:Balance Sheet (B/S)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2020年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2019年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2018年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2017年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Balance Sheet 2016年3月期

[Show - Hide] Balance Sheet (B/S)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017 March 31, 2016
Cash and Cash Equivalents 45,307 37,856 30,532 23,924 23,073
Other Current AssetsHelp 84,801 78,546 79,518 77,024 78,679
Tangible Fixed AssetsHelp 48,460 47,421 47,193 45,834 48,040
Intangible Fixed AssetHelp 1,945 2,482 2,605 1,928 2,372
Investments and OthersHelp 31,415 33,565 36,815 32,098 26,279
Total AssetsHelp 215,301 200,953 198,166 181,543 179,573
Total Current LiabilitiesHelp 70,828 68,198 68,713 61,776 67,729
Total Long-term LiabilitiesHelp 5,190 1,483 1,768 1,765 1,035
Shareholder's EquityHelp 139,283 131,272 127,685 118,002 110,809
Total LiabilitiesHelp 215,301 200,953 198,166 181,543 179,573

ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account(P/L)

[表示非表示] U-Chart:Profit and Loss Account (P/L)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2020年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2019年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2018年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2017年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Profit and Loss Account 2016年3月期

[Show - Hide] Profit and Loss Account (P/L)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017 March 31, 2016
Amount of Sales 188,327 183,582 171,742 154,599 167,016
Total Sales 188,327 183,582 171,742 154,599 167,016
Cost of SalesHelp 74,135 74,048 70,746 63,254 67,250
Other Costs and RevenueHelp 98,782 99,735 91,707 81,333 90,668
Total CostsHelp 172,917 173,783 162,453 144,587 157,918
Net RevenueHelp 114,192 109,534 100,996 91,345 99,766
Earnings Before TaxHelp 21,730 16,300 16,820 14,752 14,303
Net IncomeHelp 15,410 9,799 9,289 10,012 9,098
Net Income 15,410 9,799 9,289 10,012 9,098

ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement(C/F)

[表示非表示] U-Chart:Cash Flow Statement (C/F)Help Icon

【Left:Outgoing Money】 【Right:Incoming Money】

ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2020年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2019年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2018年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2017年3月期 ROHTO PHARMACEUTICAL CO.,LTD. Cash Flow Statement 2016年3月期

[Show - Hide] Cash Flow Statement (C/F)Help  ※Unit:Millions of Yen

Accounting Date March 31, 2020 March 31, 2019 March 31, 2018 March 31, 2017 March 31, 2016
Operating Cash Flow(OFC)Help 19,109 21,744 19,625 13,450 11,364
Investing Cash Flow(ICF)Help -9,405 -10,245 -11,014 -9,511 -6,066
Financing Cash FlowHelp -1,603 -3,386 -1,823 -2,335 -5,898
Exchange Difference of Cash and Cash EquivalentsHelp -781 -832 -191 -633 -1,998
Net Increase and Decrease in Cash and Cash Equivalentsn 7,320 7,281 6,597 971 -2,598

他社比較Help

Companies in 'Companies Comparison' list

Browsing historyHelp

Your reecently viewed companies

ROHTO PHARMACEUTICAL CO.,LTD.

Company where related level is highHelp

KYORIN Holdings,Inc.
D.Western Therapeutics Institute, Inc.
Toyama Chemical Co.,Ltd.
RIBOMIC Inc.
CanBas Co.,Ltd.
ASKA Pharmaceutical Co.,Ltd.
TAIKO PHARMACEUTICAL CO.,LTD.
NanoCarrier Co.,Ltd.
R-TECH UENO,LTD.
Modalis Therapeutics Corporation